Marketing: SOMAÍ Pharmaceuticals October 2023 Newsletter
As we approach the final months of the year, we’re excited to share our latest updates and developments from October. It was a month filled with significant events and advancements that reaffirmed our commitment to excellence in the pharmaceutical industry.
In October, SOMAÍ Pharmaceuticals took the global stage by participating in the prestigiousCPHIconference held in Barcelona, Spain. This international event allowed us to connect with key stakeholders in the pharmaceutical industry and showcase our commitment to cutting-edge pharmaceutical solutions. More and more large pharmaceutical companies worldwide are eyeing their entrance, and SOMAÍ will participate next year in Milan due to the amazing interest shown.
SOMAÍ Pharmaceuticals believes in the power of collaboration and knowledge sharing. In October, our Research and Development team engaged with esteemed cannabis researchers at our second Scientific Advisory Board meeting: Dr.Anne Katrin Schlag, Dr.Dedi Meiri, Dr. Mauro Maccarone, andAlexander Daske. Discussions during the meeting centered around in-vivo models for SOMAÍ’s upcoming pharmacokinetics studies. Furthermore, the relevance of observational studies, particularly in coordination with randomized trials, was explored. This collective effort ensures that we continue to push the boundaries of pharmaceutical research.
To further enhance our capabilities, SOMAÍ Pharmaceuticals made a strategic investment in state-of-the-art Soft Gel Filling and Blister Packaging Machines. This advanced machinery will significantly contribute to improving the precision and quality of our soft gel capsule production, aligning with our commitment to innovation and reliability. Besides traditional soft gels, we will be making a unique pharmaceutical tasty soft gel that will revolutionize how people consume cannabis in the EU.
We’re thrilled to announce that our Quality Control team has successfully implemented a new Laboratory Information Management System (LIMS). This system promises to enhance productivity and quality in our operations, ensuring that our products continue to meet the highest standards of quality and safety. SOMAÍ is committed to technology, and soon, our Electronic Batch Records (EBR) will complete a technology-superior company that reduces error and reporting by three systems ERP, LIMS and EBR all working towards paperless and seamless manufacturing.
SOMAÍ Pharmaceuticals has created new packaging for our upcoming pharmaceutical products. These enhancements reflect our dedication to ensuring that our products are not only effective but also well-presented and convenient for our patients and healthcare partners.
Our CEO, Michael Sassano, continues to develop our Australian sales footprint and was a participant at the AUSbiotech conference held in Melbourne, Australia, at the end of October. His presence at such important gatherings underlines our commitment to staying at the forefront of industry trends and innovations. He has been traveling to many countries and, most recently, to Morocco to help pharmaceutical companies enter the cannabis space.
In conclusion, October was an exciting and productive month for SOMAÍ Pharmaceuticals, marked by international engagement, investment in cutting-edge technology, and a relentless commitment to quality and innovation.
SOMAÍ – November highlights:
In November, CEO Michael Sassano remains engaged on the international stage. In November, he continues his presence in Australia before heading to MJ Bizcon at the end of the month. These engagements enable us to foster global partnerships, exchange knowledge, and stay at the forefront of industry trends.
We are excited to announce the commencement of production for the first batch of our soft gel capsules and oral sprays. Additionally, we will be introducing a unique line of terpene-enhanced products, which we will reveal in due time, showcasing our unwavering dedication to constant innovation.
As we move forward into November, we are excited to embrace new challenges and opportunities. Our focus remains on advancing pharmaceutical research, delivering top-notch products, and fostering strong partnerships.